title: New-onset paresthesias in inflammatory bowel disease.
authors.affiliation: Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Simonetto
authors.affiliation: Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
authors.forename: Konstantinos A
authors.initials: KA
authors.lastname: Papadakis
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001706:Biopsy; D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D010292:Paresthesia / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D012074:Remission Induction; D012307:Risk Factors; D012507:Sarcoidosis / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D013116:Spinal Cord / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab